Fran Curtis is a five-time survivor of cancers survivor including breast, appendix and skin cancer, but she told CURE in a ...

Inlexzo is supplied as a single-dose intravesical system containing 225mg of gemcitabine plus a sterile urinary catheter and stylet.

To our knowledge, SunRISe-4 shows, for the first time, a benefit of the addition of the localised TAR-200 gemcitabine intravesical system to systemic checkpoint inhibition as neoadjuvant treatment in ...

The potential of moving the combination to the earlier MIBC setting significantly increases the Padcev market.

Petros Grivas, MD, PhD, discusses the overall survival and quality-of-life findings from the JAVELIN Bladder 100 trial of ...

CG Oncology Inc. (NASDAQ:CGON) is one of the best hot stocks to invest in. On October 8, Guggenheim analyst Brad Canino ...

The first iteration of HER2-targeted drugs showed limited activity in bladder cancer, but the rise of antibody-drug ...

The NIAGARA trial showed that adding durvalumab to neoadjuvant chemotherapy in MIBC patients did not negatively impact HRQOL outcomes. Significant improvement in event-free survival was observed with ...

Dr. Kates’ experience as chair of the landmark Phase 3 BRIDGE bladder cancer trial and dedication to patient care will be invaluable to the ...

The mission with cancer therapy is clear: eradicate as many tumour cells as possible. Traditional chemotherapy remains a mainstay, where patients are dosed with potent compounds that disrupt essential ...

Beijing Time (09:00 am Berlin Time) on October 20, the Global Launch Event for Iza-bren (EGFR×HER3 Bispecific ADC) ...

Long-term trial findings support use of neoadjuvant chemotherapy in patients with high-risk localized upper tract urothelial carcinoma (UTUC).